In 2004 we developed a draft position statement on our future use of energy, which will be finalised in 2005. This was in response to feedback showing that energy use is a key area of concern among our stakeholders. The draft position sets out a strategy for reducing greenhouse gas emissions through energy efficiency, renewable energy and emissions trading. It also acknowledges that climate change may affect disease patterns and proposes that GSK should support research to help society plan for the consequences of climate change.
In 2004, we continued to work on a number of energy efficiency initiatives. For example, in the UK GSK partnered with the Carbon Trust to reduce energy consumption through energy audits and raising employees’ awareness. In the US we joined the Energy Star programme which encourages businesses to increase their energy efficiency and share best practice.
In the UK, we installed two wind turbines at our Barnard Castle facility.
A number of our UK sites are participating in the government's emissions trading scheme (ETS) - helping us to gain experience in carbon trading. The UK ETS is a voluntary scheme which rewards companies that improve energy efficiency with reductions in the tax they pay on energy consumption. Sites that keep emissions below an agreed target can bank the spare credits to help with compliance in subsequent years or can sell the credits to other participants in the scheme. By the end of 2004, GSK had banked more than 50,000 carbon credits which can be used to help us keep within targets in the future. We plan to participate in the EU Emissions Trading Scheme which began at the start of 2005. We estimate that more than 50% of our carbon dioxide emissions from energy worldwide will be regulated under the EU Scheme.
Year |
Steam imported |
Electricity imported |
Non-transport fuels |
|---|---|---|---|
|
(million gigajoules)
|
|||
2001 |
0.3 |
8.1 |
12.2 |
2002 |
0.1 |
8.2 |
11.7 |
2003 |
0.2 |
8.2 |
11.6 |
2004 |
0.2 |
7.8 |
11.0 |
| Per unit sales as percentage of 2001 baseline | ||||
|---|---|---|---|---|
2001 |
2002 |
2003 |
2004 |
2005 |
100% |
94.1% |
92.7% |
93.1% |
92.0% |
Back to top
| Business | 2001 |
2002 |
2003 |
2004 |
|---|---|---|---|---|
(million gigajoules) |
||||
| 01. R&D | 5.11 |
4.80 |
4.91 |
4.84 |
| 02. Biologicals | 1.23 |
1.22 |
1.32 |
1.32 |
| 03. Consumer healthcare | 1.90 |
1.90 |
2.01 |
2.15 |
| 04. New product and global supply | 2.03 |
2.05 |
2.02 |
2.04 |
| 05. Regional pharma supply | 2.03 |
1.95 |
1.75 |
1.77 |
| 06. Primary supply and antibiotics | 7.93 |
7.24 |
6.85 |
5.77 |
| 07. Commercial | 0.04 |
0.63 |
0.83 |
0.87 |
| 08. Other | 0.26 |
0.21 |
0.23 |
0.23 |
Back to top
Year |
Steam imported |
Electricity imported |
Non-transport fuels |
|---|---|---|---|
|
(million kg CO2 equivalent)
|
|||
2001 |
37 |
1,107 |
748 |
2002 |
9 |
1,116 |
714 |
2003 |
11 |
1,117 |
705 |
2004 |
11 |
1,061 |
677 |
| Per unit sales as percentage of 2001 baseline | ||||
|---|---|---|---|---|
2001 |
2002 |
2003 |
2004 |
2005 |
100% |
93.9% |
92.8% |
93.1% |
92.0% |
Back to top
| Business | 2001 |
2002 |
2003 |
2004 |
|---|---|---|---|---|
(million kg CO2 equivalent) |
||||
| 01. R&D | 499.71 |
464.5 |
474.54 |
468.49 |
| 02. Biologicals | 80.75 |
80.62 |
86.92 |
87.61 |
| 03. Consumer healthcare | 208.27 |
201.73 |
208.58 |
223.73 |
| 04. New product and global supply | 178.90 |
180.30 |
172.51 |
172.86 |
| 05. Regional pharma supply | 214.69 |
205.83 |
185.29 |
178.87 |
| 06. Primary supply and antibiotics | 674.28 |
623.87 |
598.57 |
509.17 |
| 07. Commercial | 5.99 |
66.52 |
88.08 |
90.16 |
| 08. Other | 29.37 |
15.78 |
18.74 |
18.77 |
Back to top
This section contains information in several formats:
To download PDF files you will need Adobe Reader. If you do not have it installed, it is available free from the Adobe website. PDF links on this site open in a new window.
For audio-visual content you can use either Windows Media Player or Real Player, which can be installed free from their respective websites.